Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2018

01-09-2018 | Breast Oncology

Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial

Authors: Walter Paul Weber, MD, Christoph Tausch, MD, Stefanie Hayoz, PhD, Mathias Konrad Fehr, MD, Karin Ribi, PhD, Hanne Hawle, MD, Judith Eva Lupatsch, PhD, Klazien Matter-Walstra, PhD, Federica Chiesa, MD, Konstantin Johannes Dedes, MD, Gilles Berclaz, MD, Loic Lelièvre, MD, Thomas Hess, MD, Uwe Güth, MD, Verena Pioch, MD, Dimitri Sarlos, MD, Cornelia Leo, MD, Claudia Canonica, MD, Natalie Gabriel, MD, Jasmin Zeindler, MD, Estelle Cassoly, PhD, Christiane Andrieu, PhD, Savas Deniz Soysal, MD, Thomas Ruhstaller, MD, Peter Martin Fehr, MD, Michael Knauer, MD, PhD, for the Swiss Group for Clinical Cancer Research (SAKK)

Published in: Annals of Surgical Oncology | Issue 9/2018

Login to get access

Abstract

Background

Several studies and a meta-analysis showed that fibrin sealant patches reduced lymphatic drainage after various lymphadenectomy procedures. Our goal was to investigate the impact of these patches on drainage after axillary dissection for breast cancer.

Methods

In a phase III superiority trial, we randomized patients undergoing breast-conserving surgery at 14 Swiss sites to receive versus not receive three large TachoSil® patches in the dissected axilla. Axillary drains were inserted in all patients. Patients and investigators assessing outcomes were blinded to group assignment. The primary endpoint was total volume of drainage.

Results

Between March 2015 and December 2016, 142 patients were randomized (72 with TachoSil® and 70 without). Mean total volume of drainage in the control group was 703 ml [95% confidence interval (CI) 512–895 ml]. Application of TachoSil® did not significantly reduce the total volume of axillary drainage [mean difference (MD) −110 ml, 95% CI −316 to 94, p = 0.30]. A total of eight secondary endpoints related to drainage, morbidity, and quality of life were not improved by use of TachoSil®. The mean total cost per patient did not differ significantly between the groups [34,253 Swiss Francs (95% CI 32,625–35,880) with TachoSil® and 33,365 Swiss Francs (95% CI 31,771–34,961) without, p = 0.584]. In the TachoSil® group, length of stay was longer (MD 1 day, 95% CI 0.3–1.7, p = 0.009), and improvement of pain was faster, although the latter difference was not significant [2 days (95% CI 1–4) vs. 5.5 days (95% CI 2–11); p = 0.2].

Conclusions

TachoSil® reduced drainage after axillary dissection for breast cancer neither significantly nor relevantly.
Appendix
Available only for authorised users
Literature
1.
Droeser RA, Frey DM, Oertli D et al. Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis. Breast. 2009;18:109–14.CrossRefPubMed
2.
He XD, Guo ZH, Tian JH et al. Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials. Med Oncol. 2011;28(Suppl 1):S22–30.CrossRefPubMed
3.
Gauthier T, Garuchet-Bigot A, Marin B et al. Lanreotide autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial. Eur J Surg Oncol. 2012;38(10):902–9.CrossRefPubMed
4.
O’Hea BJ, Ho MN, Petrek JA. External compression dressing versus standard dressing after axillary lymphadenectomy. Am J Surg. 1999;177:450–3.CrossRefPubMed
5.
Shamley DR, Barker K, Simonite V, et al. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. Breast Cancer Res Treat. 2005;90:263–71.CrossRefPubMed
6.
van Bemmel AJ, van de Velde CJ, Schmitz RF, et al. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011;37:829–35.CrossRefPubMed
7.
Cipolla C, Fricano S, Vieni S, et al. Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients. J Surg Oncol. 2010;101:600–3.CrossRefPubMed
8.
Gilly FN, Francois Y, Sayag-Beaujard AC, et al. Prevention of lymphorrhea by means of fibrin glue after axillary lymphadenectomy in breast cancer: prospective randomized trial. Eur Surg Res. 1998;30:439–43.CrossRefPubMed
9.
Ko E, Han W, Cho J, et al. Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009;24:92–6.CrossRefPubMedPubMedCentral
10.
Ruggiero R, Procaccini E, Gili S, et al. Fibrin glue to reduce seroma after axillary lymphadenectomy for breast cancer. Min Chir. 2008;63:249–54.
11.
Swan MC, Oliver DW, Cassell OC, et al. Randomized controlled trial of fibrin sealant to reduce postoperative drainage following elective lymph node dissection. Br J Surg. 2011;98:918–24.CrossRefPubMed
12.
Taflampas P, Sanidas E, Christodoulakis M, et al. Sealants after axillary lymph node dissection for breast cancer: good intentions but bad results. Am J Surg. 2009;198:55–8.CrossRefPubMed
13.
Carless PA, Henry DA. Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg. 2006;93:810–9.CrossRefPubMed
14.
Buda A, Fruscio R, Pirovano C, et al. The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy. Int J Gynaecol Obstet. 2012;117:217–9.CrossRefPubMed
15.
15. Buda A, Ghelardi A, Fruscio R, et al. The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study. Eur J Obstet Gynecol Reprod Biol. 2016;197:156–8.CrossRefPubMed
16.
Di MG, Caraco C, Crispo A, et al. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012;10:275.CrossRef
17.
Navarro-Rodriguez E, Gomez-Luque I, Diaz-Jimenez N, et al. Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis. Am J Surg. 2014;208:824–30.CrossRefPubMed
18.
Pinero-Madrona A, Castellanos-Escrig G, Abrisqueta-Carrion J, et al. Prospective randomized controlled study to assess the value of a hemostatic and sealing agent for preventing seroma after axillary lymphadenectomy. J Surg Oncol. 2016;114:423–7.CrossRefPubMed
19.
Gasparri ML, Ruscito I, Bolla D, et al. The efficacy of fibrin sealant patches in reducing the incidence of lymphatic morbidity after radical lymphadenectomy: a meta-analysis. Int J Gynecol Cancer. 2017;27:1283–92.CrossRefPubMed
20.
Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20:250–78.
21.
22.
Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129–38.PubMed
23.
Antonio M, Pietra T, Domenico L, et al. Does LigaSure reduce fluid drainage in axillary dissection? A randomized prospective clinical trial. Ecancermedicalscience. 2007;1:61.PubMedPubMedCentral
24.
Chintamani, Singhal V, Singh J, et al. Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer- a prospective randomized clinical trial [ISRCTN24484328]. BMC Cancer. 2005;5:11.
25.
Classe JM, Berchery D, Campion L, et al. Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. Br J Surg. 2006;93:820–4.CrossRefPubMed
26.
Cortadellas T, Cordoba O, Espinosa-Bravo M, et al. Electrothermal bipolar vessel sealing system in axillary dissection: a prospective randomized clinical study. Int J Surg. 2011;9:636–40.CrossRefPubMed
27.
Yang Y, Gao E, Liu X, et al. Effectiveness of OK-432 (Sapylin) to reduce seroma formation after axillary lymphadenectomy for breast cancer. Ann Surg Oncol. 2013;20(5):1500–4.CrossRefPubMed
28.
Zavotsky J, Jones RC, Brennan MB, et al. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. Ann Surg Oncol. 1998;5:227–31.CrossRefPubMed
29.
Barry M, Weber WP, Lee S, et al. Enhancing the clinical pathway for patients undergoing axillary lymph node dissection. Breast. 2012;21:440–3.CrossRefPubMed
30.
Baas-Vrancken Peeters MJ, Kluit AB, Merkus JW, et al. Short versus long-term postoperative drainage of the axilla after axillary lymph node dissection. A prospective randomized study. Breast Cancer Res Treat. 2005;93:271–5.CrossRefPubMed
31.
Dalberg K, Johansson H, Signomklao T, et al. A randomised study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. Eur J Surg Oncol. 2004;30:602–9.CrossRefPubMed
32.
Gong Y, Xu J, Shao J, et al. Prevention of seroma formation after mastectomy and axillary dissection by lymph vessel ligation and dead space closure: a randomized trial. Am J Surg. 2010;200:352–6.CrossRefPubMed
33.
Briceno J, Naranjo A, Ciria R, et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg. 2010;145:482–8.CrossRefPubMed
34.
Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149:48–55.CrossRefPubMed
35.
Frilling A, Stavrou GA, Mischinger HJ, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390:114–20.CrossRefPubMed
36.
Genyk Y, Kato T, Pomposelli JJ, et al. Fibrin sealant patch (Tachosil) vs oxidized regenerated cellulose patch (Surgicel original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222:261–8.CrossRefPubMed
37.
Kakaei F, Seyyed Sadeghi MS, Sanei B, et al. A randomized clinical trial comparing the effect of different haemostatic agents for haemostasis of the liver after hepatic resection. HPB Surg. 2013;2013:587–608.CrossRef
38.
Rickenbacher A, Breitenstein S, Lesurtel M, et al. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery—a systematic review. Expert Opin Biol Ther. 2009;9:897-907.CrossRefPubMed
39.
Berger A, Tempfer C, Hartmann B, et al. Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study. Breast Cancer Res Treat. 2001;67:9–14.CrossRefPubMed
Metadata
Title
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial
Authors
Walter Paul Weber, MD
Christoph Tausch, MD
Stefanie Hayoz, PhD
Mathias Konrad Fehr, MD
Karin Ribi, PhD
Hanne Hawle, MD
Judith Eva Lupatsch, PhD
Klazien Matter-Walstra, PhD
Federica Chiesa, MD
Konstantin Johannes Dedes, MD
Gilles Berclaz, MD
Loic Lelièvre, MD
Thomas Hess, MD
Uwe Güth, MD
Verena Pioch, MD
Dimitri Sarlos, MD
Cornelia Leo, MD
Claudia Canonica, MD
Natalie Gabriel, MD
Jasmin Zeindler, MD
Estelle Cassoly, PhD
Christiane Andrieu, PhD
Savas Deniz Soysal, MD
Thomas Ruhstaller, MD
Peter Martin Fehr, MD
Michael Knauer, MD, PhD
for the Swiss Group for Clinical Cancer Research (SAKK)
Publication date
01-09-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6556-9

Other articles of this Issue 9/2018

Annals of Surgical Oncology 9/2018 Go to the issue

Urologic Oncology

Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer

Melanomas

1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study

Bone and Soft Tissue Sarcomas

Resection of a Perirectal Leiomyosarcoma via a Posterior Transcoccygeal Approach

Breast Oncology

Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Gastrointestinal Oncology

Young Age and Risk of Lymph Node Metastasis in Differentiated Type Early Gastric Cancer

Hepatobiliary Tumors

Long-Term Oncologic Outcomes Following Robotic Liver Resections for Primary Hepatobiliary Malignancies: A Multicenter Study